Introduction

M
umps is caused by a virus (MuV) belonging to the family Paramixoviridae. 1, 2 The disease usually occurs among children and in the pre-vaccine era the annual reported mumps incidence in Western European countries ranged between 100 and 600 per 100 000 inhabitants. 3 With the availability of a liveattenuated mumps vaccine since the 1960s, 4 disease incidence dramatically decreased in countries with mumps vaccination programmes. 5, 6 However, several outbreaks of mumps have occurred among measles, mumps and rubella (MMR) vaccinated individuals in various countries worldwide. [7] [8] [9] [10] Like measles and rubella (MR), mumps is efficiently transmitted from person to person. Before the start of extended programmes of immunization, mumps was typically a childhood disease, with the highest incidence among children between 5 and 9 years of age, presenting with a generally benign course, which is asymptomatic in about one third of the infected children. However, mumps may affect people of any age, causing more severe complications among adults. Clinical mumps is defined as the acute onset of unilateral or bilateral tender, self-limiting swelling of the parotid or other salivary glands (from which the popular name 'mumps'), lasting two or more days without other apparent cause. Swelling of the parotid glands is the most important clinical sign and may result in pain associated with chewing and swallowing. Fever and malaise are also common. Chills, headache, and a slight rise in temperature may occur $24 h before the onset of parotid swelling. In total 15-20% of mumps infections can be asymptomatic and about 50% are associated with non-specific or respiratory symptoms. [11] [12] [13] Children with mumps usually recover within few days after symptoms onset. The most common complications include encephalitis (0.02-0.3%), meningitis (0.5-15%), pancreatitis (4%) and hearing loss. Finally, infection during the first 12 weeks of pregnancy is associated with a high percentage of miscarriages (25%), but not the risk of fetal malformations. 2 When parotitis is present during a mumps outbreak or epidemic, the clinical diagnosis of mumps is generally straightforward. However, when the incidence rate of mumps is low, other causes of parotitis, in particular viral infections such as those due to the Epstein-Barr virus (EBV), parainfluenza viruses, influenza A virus, coxsackieviruses, adenoviruses, parvovirus B19, lymphocytic choriomeningitis virus and HIV, should be considered. 12, 14 For this reason, an approach based on the laboratory testing is essential to confirm the clinical suspicion of mumps, especially in areas where the incidence of the disease is low.
In Italy, mumps diagnosis is performed within the framework of MR surveillance. Indeed, to support case ascertainment, the National Reference Laboratory (NRL) for MR performs laboratory surveillance to confirm suspected cases of measles, rubella and mumps. 15 In February 2013, the Italian Minister of Health published a document which regulates the integrated surveillance for MR in which indications about the laboratory mumps surveillance were further included. 16 This retrospective study investigated whether the etiology of Italian sporadic suspected mumps cases with a negative molecular/ serological result for mumps virus obtained at the NRL, in 2007-16, were due to EBV, in order to establish a diagnosis.
Methods
Mumps case definition
The case definition and classification is that stipulated by EU Commission Decision of 8 August 2012.
Clinical criteria
Fever and at least two of the following: sudden onset of unilateral or bilateral tender swelling of the parotid or other salivary glands without other apparent cause or orchitis or meningitis.
Laboratory criteria
At least two of the following (i) isolation of mumps virus from a clinical specimen; (ii) detection of mumps virus nucleic acid; (iii) MuV specific antibody response characteristic for acute infection in serum or saliva.
Epidemiological criteria
An epidemiological link by human-to-human transmission.
Case classification includes 'possible case' (any person meeting the clinical criteria), 'probable case' (any person meeting the clinical criteria and with an epidemiological link), 'confirmed case' (any person not recently vaccinated and meeting the clinical and the laboratory criteria). Mumps virus genome can be detected from oral fluid within the first week after symptoms onset. Oral fluid from suspected mumps cases were tested for mumps by RT Real-Time PCR, while blood samples were tested for specific IgM anti-mumps detection by Elisa. Oral fluid samples still available of those negative patients were further tested for EBV by PCR.
Study population and clinical samples
Serological diagnosis for mumps
The detection of anti-mumps IgM was performed with the Enzygnost Anti-Parotitis Virus/IgM kit (Dade/Behring, Siemens) on blood samples collected and treated as previous described in. 17 
Molecular detection of mumps and EBV
RNA and DNA were extracted from oral fluid specimens using QIAmp Viral RNA Kit and QIAamp DNA Mini Kit (Qiagen), respectively, according to the manufacturer's instructions.
A 7 ml aliquot of RNA was used for a reverse transcription PCR Real-time with the RealTime Ready RNA Virus Master kit (Roche) according to CDC's indications. 18 A portion of 169 bp of the BXLF1 gene of EBV was amplified by PCR. The reaction was performed with PCR Supermix (Invitrogen), 10 pmol of each forward (EBV1 5 0 -GGGGCAAAATACTGTGTTAG-3 0 , position 143 411) and reverse primers (EBV2 5 0 -CGGGGGAC ACCATAGT-3 0 , position 143 579), and 3 ml of extracted DNA. 19 The cycling conditions consisted of an initial denaturation of 10 s at 95 C, followed by 45 cycles of 40 s at 95 C, 1 min at 58 C and 40 s at 72 C and a final extension of 5 min at 72 C.
Genetic analysis
Samples positive for MuV were further amplified for genotyping by PCR followed by a Nested PCR on the MuV SH gene, 20 using the SuperScript One-Step RT-PCR with PlatinumR Taq System and PCR SuperMix kits (Invitrogen), respectively. Before sequencing, PCR products were purified with the QIAquick PCR Purification Kit (QIAGEN) and sequencing reactions performed by Macrogen Inc. (Seoul, South Korea). Nucleotide sequences were aligned with sequences of the reference strains and with those that showed a high percentage of identity after Blast analysis, using CLUSTAL W (BioEdit) software. 21 The Bayesian Information Criterion was used to determine the model of nucleotide substitution that best fit the data using the selection tool available in MEGA6. 22 Evolutionary analyses were conducted using the maximum likelihood method based on the Tamura 3-parameter (T92) model and evolutionary rates among sites were modelled by a discrete Gamma distribution (+G).
Samples positive for EBV were tested by PCR to amplify a portion of the gene EBNA3C in order to discriminate between EBV genotype type 1 or type 2.
23 PCR was performed with PCR Supermix (Invitrogen) with 5 min at 95 C, followed by 35 cycles of 45 s at 95 C, 45 s at 56 C and 1 min at 72 C and 10 min at 72 C. Amplicons were analysed by electrophoresis on 1.5% agarose gel and gel-red staining.
Results
From June 2007 to 2016, 148 oral fluid and 169 blood samples from a total of 193 patients with suspect mumps were collected and tested at the NRL. As reported in table 1, 11/193 (5.7%) patients were found positive for MuV infection either by serological or molecular assay, and 182 were negative. Three cases were positive by IgM serology but negative by PCR probably due a bad sampling. Detailed results and vaccination status for each positive patient are reported in table 2. Vaccination status was available for 9 out of 11 positive cases: 5 mumps infected patients had received one dose of MMR vaccine, 2 patients had received two doses and 2 were not vaccinated. For five patients, it was possible to calculate the time elapsed after vaccination (ranging from 2.5 to 13 years). For those negative cases, 66.5% (121/182) had received at least one dose of vaccine against mumps while 20.9% (38/182) were not vaccinated.
Phylogenetic analysis was performed on 5 MuV sequences obtained from samples positive in PCR. As shown in figure 1,  four Oral fluid samples available for 131 out of 182 mumps negative cases were further tested for EBV by PCR; of them, 26 were found positive (positivity rate of 19.8%) for viral DNA (table 1) .
Beside genetic analysis on mumps strains, EBV positive samples were tested by PCR to distinguish between genotypes type 1 or 2, and all of them belonged to genotype 1.
The incidence trend of new cases of mumps in Italy from 1996 to 2014 shows a series of oscillations, with a maximum of almost 65 000 cases reported in 1996 (figure 2). Since 1999, the incidence of mumps declined to a minimum number of 191 cases reported in 2014. This decline was probably due to MMR vaccination campaigns. Studies established that the effectiveness of any MMR vaccination in patients with a history at least one MMR vaccination adjusted for age, sex and general practice was 69% (95% CI: 41-84%) 24, 25 and because of the low effectiveness of the mumps MMR vaccine component, several outbreaks occurred in Europe. 26, 27 Also, the decreased efficiency of the surveillance system, leading to a low notification rate, was likely to contribute to the low number of cases reported in Italy in the last years.
The standard clinical case definition of mumps used for surveillance activities consisted in 'acute onset of unilateral or bilateral swelling of the parotid or other salivary glands lasting two or more days without any other apparent cause'. 2 However, although parotitis is indeed the hallmark of mumps, there are cases in which salivary-gland swelling is not apparent, especially in individuals with mumps meningitis, many of whom do not present detectable salivary-gland enlargement. 28, 29 Moreover, other infectious agents may also cause salivary-gland swelling. The effect of such alternative aetiologies greatly reduces the positive predictive value of a clinical diagnosis when the disease incidence is low. 30 This study reports results from the differential diagnosis of mumps with EBV-related mononucleosis provides information on the specificity of the clinical diagnosis of mumps, suggesting the importance of laboratory confirmation. Our findings show that the specificity of the case-definition of mumps is low. Studies conducted in other areas of the world provided similar results. In a study conducted in Victoria, Australia, only 7 (9%) of 74 cases clinically diagnosed as mumps parotitis could be confirmed by serology; 7 (16%) of 43 laboratoryrejected cases were positive for EBV using serological testing. 30 In a study conducted in Finland, on 601 acutely ill children presenting mumps-like symptoms but seronegative for mumps, the most commonly identified viral agents were the EBV (7%), parainfluenza virus (4%) and adenovirus (3%). 31 These studies highlight the importance of laboratory confirmation in diagnosing mumps, especially under non-outbreak conditions.
Discussion
According to WHO, introduction of routine mumps vaccination, such as other prophylactic options, 31 should be a high priority. Most European health systems provide mumps vaccine in combination with MMR, with a two-dose vaccination schedule, free of charge, and some 120 countries have introduced vaccination against mumps in their national immunization programmes. To date, countries such as Finland or Sweden have completely eradicated mumps from their national territory. 32 Actions should be implemented to encourage practitioners to collect oral and blood samples from mumps suspected cases and to submit these samples to the NRL or other reference labs that performs mumps virus PCR and serology. This is of special importance when the patient is vaccinated and a primary or secondary vaccination failure is suspected, being important both for individual patients and for monitoring the outcome of vaccination programmes. About that, our study revealed that three patients positive for mumps had been vaccinated before the introduction (in 2001) of the more efficient component Urabe AM 9 in the MMR vaccine in spite of the Rubini strain, responsible for some vaccine failure. 33 In conclusion, the results of this study confirm the importance of a lab-based differential diagnosis that can discriminate between different infectious diseases presenting with symptoms suggestive of mumps and emphasize the importance to discriminate between mumps and EBV-related mononucleosis. Finally, the large proportion of negative results suggests that other viral infections are involved in the genesis of mumps-like syndromes.
Funding
This work was partially funded by the Italian Ministry of Health grant CCM 2015-6M21.
Conflicts of interest: None declared.
Key points
The specificity of the case-definition of mumps is low and a large number of viral infections are involved in the genesis of mumps-like syndromes such as Epstein-Barr virus. A lab-based differential diagnosis is essential to discriminate between different infectious diseases, especially for the large proportion of mumps negative cases. Low efficiency of the surveillance system for mumps, leading to a low notification rate, contribute to the low number of cases reported in Italy in the last years. 
